Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
ISO/TS 27265:2019 – Nanotechnologies – In Vitro Measurement of Engineered Nanomaterial Toxicity
Comprehensive guidance on measurement considerations, interference mitigation, and best practices for in vitro nanotoxicity testing
Nanoparticle interference with assay readouts is the single most important source of error in nanotoxicity testing. Up to 30% of published nanotoxicity data may be compromised by unrecognized assay interferences. Always include appropriate controls.
Always characterize nanomaterials in the actual test medium (not just in water or buffer). The protein corona formed in serum-containing media dramatically alters nanoparticle surface properties and should be characterized alongside the pristine material.
Introduction to ISO/TS 27265:2019
ISO/TS 27265:2019 provides essential guidance on the measurement of engineered nanomaterial toxicity using in vitro methods. As the commercial production of nanomaterials continues to grow, understanding their potential toxicological effects is paramount for worker safety, consumer protection, and environmental health. This technical specification addresses the unique challenges that nanomaterials present to conventional in vitro toxicity testing protocols – challenges arising from their high surface reactivity, ability to adsorb assay components, and tendency to interfere with optical and biological detection systems.
The standard establishes a framework for designing, conducting, and interpreting in vitro nanotoxicity studies, with particular emphasis on identifying and mitigating artifacts that can lead to false positive or false negative results. It covers cell viability assays, oxidative stress measurements, genotoxicity testing, and inflammatory response evaluation.
Some nanoparticles (e.g., ZnO, Ag NPs, CuO) dissolve rapidly in cell culture media, releasing toxic metal ions that may be the primary cause of observed toxicity rather than particle-specific effects. Differentiate between ion toxicity and particle toxicity using dissolution controls and ion-only exposures.
Key Considerations and Interference Mitigation
ISO/TS 27265:2019 identifies several critical interference mechanisms that can compromise in vitro nanotoxicity measurements and provides mitigation strategies:
| Interference Type | Mechanism | Affected Assays | Mitigation Strategy |
|---|---|---|---|
| Optical Interference | Nanoparticle absorbance or scattering at assay wavelengths | MTT, LDH, fluorescent assays | Use cell-free controls; switch to luminescence-based assays |
| Catalytic Interference | Nanoparticle surface catalyzes assay reactions | DCFH-DA (ROS), MTS | Include catalytically inactive controls; verify with orthogonal methods |
| Adsorptive Interference | Nanoparticles adsorb assay reagents, proteins, or dyes | Protein quantification, enzyme assays | Centrifuge to remove nanoparticles; use mass spectrometry-based readouts |
| Cytokine Adsorption | ELISA detection antibodies bind to nanoparticles | Cytokine quantification | Centrifuge supernatant before ELISA; spike-and-recovery controls |
The standard emphasizes that no single assay is sufficient for nanotoxicity assessment. A battery of complementary assays with orthogonal readout mechanisms is necessary to distinguish genuine toxic effects from measurement artifacts.
By implementing the interference control and dose characterization protocols recommended in ISO/TS 27265, laboratories can reduce inter-experiment variability in nanotoxicity assays from more than 50% to less than 15% coefficient of variation, dramatically improving data quality and reproducibility.
Engineering Design Insights and Best Practices
A fundamental engineering insight from ISO/TS 27265:2019 is that nanomaterial physicochemical characterization must be performed under conditions that match the in vitro test environment – not just the pristine material. The effective particle size, agglomeration state, surface charge (zeta potential), and dissolution rate can change drastically when nanomaterials are dispersed in cell culture media containing serum proteins. These changes directly influence the cellular dose and toxicological response.
Dose Metrics and Reporting
Traditional toxicology uses mass concentration (microg/mL) as the dose metric. However, for nanomaterials, this can be misleading because particle number, surface area, and surface reactivity often correlate better with biological response than mass. ISO/TS 27265 recommends reporting dose in multiple metrics – mass concentration, particle number concentration, and surface area concentration – to enable comprehensive interpretation. The standard also emphasizes the importance of reporting the delivered dose (the actual amount reaching cells) rather than only the administered dose, as nanoparticle settling and diffusion kinetics significantly affect cellular exposure in in vitro systems.
Frequently Asked Questions (FAQ)
Q: Why are conventional cytotoxicity assays often unreliable for nanomaterials?
A: Conventional assays (MTT, LDH, Alamar Blue) rely on optical or enzymatic readouts that can be directly interfered with by nanoparticles. Nanoparticles may absorb or scatter light at assay wavelengths, catalyze assay reactions independently of cellular activity, or adsorb assay reagents – all leading to inaccurate results. Orthogonal assay methods are essential for validation.
A: Conventional assays (MTT, LDH, Alamar Blue) rely on optical or enzymatic readouts that can be directly interfered with by nanoparticles. Nanoparticles may absorb or scatter light at assay wavelengths, catalyze assay reactions independently of cellular activity, or adsorb assay reagents – all leading to inaccurate results. Orthogonal assay methods are essential for validation.
Q: What is the protein corona and why does it matter for toxicity testing?
A: The protein corona is the layer of proteins and other biomolecules that adsorb onto nanoparticle surfaces when they are introduced into biological fluids. It fundamentally alters the nanoparticle size, surface charge, and biological identity. Cells interact with the corona-coated nanoparticle rather than the pristine surface, making corona characterization essential for understanding the biological response.
A: The protein corona is the layer of proteins and other biomolecules that adsorb onto nanoparticle surfaces when they are introduced into biological fluids. It fundamentally alters the nanoparticle size, surface charge, and biological identity. Cells interact with the corona-coated nanoparticle rather than the pristine surface, making corona characterization essential for understanding the biological response.
Q: How should the dose be reported for in vitro nanotoxicity studies?
A: ISO/TS 27265 recommends reporting at least three dose metrics: mass concentration (microg/mL), particle number concentration (particles/mL), and surface area concentration (cm2/mL). Additionally, the delivered dose should be calculated and reported alongside the administered dose, as gravitational settling and diffusion significantly affect actual cellular exposure.
A: ISO/TS 27265 recommends reporting at least three dose metrics: mass concentration (microg/mL), particle number concentration (particles/mL), and surface area concentration (cm2/mL). Additionally, the delivered dose should be calculated and reported alongside the administered dose, as gravitational settling and diffusion significantly affect actual cellular exposure.
📥 Standard Documents Download
No download files available yet